RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
| Status: | Completed |
|---|---|
| Conditions: | Schizophrenia, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | December 2011 |
| End Date: | December 2012 |
| Contact: | Medical Director |
| Email: | mcantillon@revivapharma.com |
REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to
placebo for the treatment of schizophrenia or schizoaffective disorder.
Inclusion Criteria:
- Patients providing informed consent prior to any study specific procedures
- Patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type,
disorganized type, catatonic type or undifferentiated type), or schizoaffective
disorder
- Patients with normal physical examination, laboratory, vital signs,and
electrocardiogram (ECG)
Exclusion Criteria:
- Patients with other primary psychiatric disorders as delirium, or bipolar I or II
disorder
We found this trial at
1
site
Click here to add this to my saved trials
